medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2026, Number 1

<< Back Next >>

Acta Med 2026; 24 (1)

GLP1 analogues and their considerations in perioperative management: a case report and review of the literature

Hernández MR, Contreras RME, Flores MRR

Language: Spanish
References: 16
Page: 43-46
PDF size: 470.58 Kb.


ABSTRACT

Currently, glucagon-like peptide 1 (GLP1) analogues have increased their use due to the acquisition of new clinical indications. However, within their physiology, the delay in gastric emptying has gained relevance in perioperative management due to its potential impact on adverse outcomes.


REFERENCES

  1. Ruze R, Liu T, Zou X, Song J, Chen Y, Xu R et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol (Lausanne). 2023; 14: 1161521. doi: 10.3389/fendo.2023.1161521.

  2. Atlas SJ, Kim K, Nhan E, Touchette DR, Moradi A, Agboola F et al. Medications for obesity management: effectiveness and value. J Manag Care Spec Pharm. 2023; 29 (5): 569-575. doi: 10.18553/jmcp.2023.29.5.569.

  3. Watanabe JH, Kwon J, Nan B, Reikes A. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022. J Am Pharm Assoc (2003). 2024; 64 (1): 133-138. doi: 10.1016/j.japh.2023.10.002.

  4. Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024; 9 (1): 234. doi: 10.1038/s41392-024-01931-z.

  5. Comisión Estatal para la Protección contra Riesgos Sanitarios de San Luis Potosí (COEPRIS). Aviso de riesgo sobre el uso indiscriminado de medicamentos como agonistas del receptor GLP-1 [Internet]. San Luis Potosí: COEPRIS; 2024 mayo 28 [citado 2025 feb 3]. Disponible en: http://coepris.slpsalud.gob.mx/index.php/373-aviso-de-riesgo-sobre-el-uso-indiscriminado-de-medicamentos-como-agonistas-del-receptor-glp-1

  6. Kindel TL, Wang AY, Wadhwa A, Schulman AR, Sharaiha RZ, Kroh M et al. Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Clin Gastroenterol Hepatol. 2024: S1542-3565(24)00910-8. doi: 10.1016/j.cgh.2024.10.003.

  7. Silveira SQ, da Silva LM, de Campos Vieira Abib A, de Moura DTH, de Moura EGH, Santos LB et al. Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy. J Clin Anesth. 2023; 87: 111091. doi: 10.1016/j.jclinane.2023.111091.

  8. Sherwin M, Hamburger J, Katz D, DeMaria S Jr. Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide. Can J Anaesth. 2023; 70 (8): 1300-1306. doi: 10.1007/s12630-023-02549-5.

  9. Gulak MA, Murphy P. Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report. Can J Anaesth. 2023; 70 (8): 1397-1400. doi: 10.1007/s12630-023-02521-3.

  10. Klein SR, Hobai IA. Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report. Can J Anaesth. 2023; 70 (8): 1394-1396. doi: 10.1007/s12630-023-02440-3.

  11. Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016; 4 (6): 525-536. doi: 10.1016/S2213-8587(15)00482-9.

  12. Das A, Geetha KM, Hazarika I. Actualizaciones contemporáneas sobre la fisiología del péptido similar al glucagón-1 y su agonista para tratar la diabetes mellitus tipo 2. Int J Pept Res Ther. 2020; 26 (3): 1211-1221. doi: 10.1007/s10989-019-09927-y.

  13. Nauck MA, Quast DR, Wefers J, Pfeiffer AFH. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update. Diabetes Obes Metab. 2021; 23 Suppl 3: 5-29. doi: 10.1111/dom.14496.

  14. Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022; 57: 101351. doi: 10.1016/j.molmet.2021.101351.

  15. Willson CM, Patel L, Middleton P, Desai M. Glucagon-like peptide-1 agonists and general anesthesia: perioperative considerations and the utility of gastric ultrasound. Cureus. 2024; 16 (4): e58042. doi: 10.7759/cureus.58042.

  16. Joshi GP, LaMasters T, Kindel TL. Preprocedure care of patients on glucagon-like peptide-1 receptor agonists: a multisociety clinical practice guidance. Anesthesiology. 2024; 141 (6): 1208-1209. doi: 10.1097/ALN.0000000000005231.




2020     |     www.medigraphic.com